Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Shattuck Labs, Inc. (STTK : NSDQ)

• Company Description    Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States. Number of Employees: 44

• Price / Volume Information    Yesterday's Closing Price: $0.95 Daily Weekly Monthly 20 Day Moving Average: 114,926 shares Shares Outstanding: 47.90 (millions) Market Capitalization: $45.40 (millions) Beta: 1.74 52 Week High: $11.76 52 Week Low: $0.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.59% -2.65% 12 Week -24.17% -18.07% Year To Date -21.66% -19.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 W. 5TH STREET SUITE 1200 - AUSTIN,TX 78701 USA ph: 512-900-4690 fax: - investorrelations@shattucklabs.com http://www.shattucklabs.com

• General Corporate Information    Officers Taylor Schreiber - Chief Executive Officer George Golumbeski - Chairman Andrew R. Neill - Chief Financial Officer Helen M. Boudreau - Director Neil Gibson - Director Peer Information Shattuck Labs, Inc. (CORR.) Shattuck Labs, Inc. (RSPI) Shattuck Labs, Inc. (CGXP) Shattuck Labs, Inc. (BGEN) Shattuck Labs, Inc. (GTBP) Shattuck Labs, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 82024L103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 47.90 Most Recent Split Date: (:1) Beta: 1.74 Market Capitalization: $45.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.67 Price/Cash Flow: - Price / Sales: 7.06 EPS Growth vs. Year Ago Period: 27.03% vs. Previous Quarter: 27.03% Sales Growth vs. Year Ago Period: 336.88% vs. Previous Quarter: 86.26% ROE 03/31/25 - -79.69 12/31/24 - -72.57 09/30/24 - -61.92 ROA 03/31/25 - -69.13 12/31/24 - -63.14 09/30/24 - -54.49 Current Ratio 03/31/25 - 9.08 12/31/24 - 8.88 09/30/24 - 7.96 Quick Ratio 03/31/25 - 9.08 12/31/24 - 8.88 09/30/24 - 7.96 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - -1,156.46 Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - -1,156.46 Pre-Tax Margin 03/31/25 - -1,532.96 12/31/24 - -1,318.13 09/30/24 - -1,156.46 Book Value 03/31/25 - 1.41 12/31/24 - 1.67 09/30/24 - 2.02 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©